

# A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Mice with Deep Vein Thrombosis Circulation Without Increasing Bleeding Risk

Science Translational Medicine

6, 222ra17

DOI: [10.1126/scitranslmed.3006804](https://doi.org/10.1126/scitranslmed.3006804)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology American Society of Hematology Education Program, 2014, 2014, 60-65.	2.5	3
2	In vivo activation and functions of the protease factor XII. Thrombosis and Haemostasis, 2014, 112, 868-875.	3.4	54
3	Thrombosis Prevention without Anticoagulation. Frontiers in Medicine, 2014, 1, 12.	2.6	0
4	Molecular mechanisms of thrombosis. Fundamental and applied aspects of the contact activation. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2014, 8, 279-289.	0.6	1
5	Extracorporeal Circulation Without Bleeding. Science Translational Medicine, 2014, 6, 222fs7.	12.4	12
6	Future prospects for contact factors as therapeutic targets. Hematology American Society of Hematology Education Program, 2014, 2014, 52-59.	2.5	19
7	Recent insights into the role of the contact pathway in thrombo-inflammatory disorders. Hematology American Society of Hematology Education Program, 2014, 2014, 60-65.	2.5	39
8	Current drugs in early development for hereditary angioedema: potential for effective treatment. Expert Opinion on Investigational Drugs, 2014, 23, 887-891.	4.1	4
9	Future Therapy for Pediatric Hereditary Angioedema. Pediatric, Allergy, Immunology, and Pulmonology, 2014, 27, 177-180.	0.8	1
10	Seeking out better anticoagulants. Nature Reviews Drug Discovery, 2014, 13, 255-255.	46.4	0
11	Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discovery Today, 2014, 19, 1459-1464.	6.4	66
12	Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay. Thrombosis Research, 2014, 134, 1335-1343.	1.7	52
13	Factor XII Regulates the Pathological Process of Thrombus Formation on Ruptured Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1674-1680.	2.4	108
14	Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. Thrombosis Research, 2014, 134, 729-736.	1.7	28
15	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thrombosis Research, 2015, 136, S13-S18.	1.7	4
16	Factor XII: a novel target for safe prevention of thrombosis and inflammation. Journal of Internal Medicine, 2015, 278, 571-585.	6.0	69
17	Medical device-induced thrombosis: what causes it and how can we prevent it?. Journal of Thrombosis and Haemostasis, 2015, 13, S72-S81.	3.8	374
18	The vascular side of plasma kallikrein. Blood, 2015, 125, 589-590.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. <i>Blood</i> , 2015, 125, 2712-2719.	1.4	40
20	The polyphosphate factor XII pathway drives coagulation in prostate cancer-associated thrombosis. <i>Blood</i> , 2015, 126, 1379-1389.	1.4	117
21	Factor XI and contact activation as targets for antithrombotic therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1383-1395.	3.8	110
22	Intravenous sufentanil-midazolam versus sevoflurane anaesthesia in medetomidine pre-medicated Himalayan rabbits undergoing ovariohysterectomy. <i>Veterinary Anaesthesia and Analgesia</i> , 2015, 42, 377-385.	0.6	8
23	Factor XII full and partial null in rat confers robust antithrombotic efficacy with no bleeding. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 893-902.	1.0	20
24	A Synthetic Factor XIIa Inhibitor Blocks Selectively Intrinsic Coagulation Initiation. <i>ACS Chemical Biology</i> , 2015, 10, 1861-1870.	3.4	64
25	How it all starts: Initiation of the clotting cascade. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2015, 50, 326-336.	5.2	303
26	Medically-Induced Hemophilia C to Treat Thrombosis. <i>Thrombosis Research</i> , 2015, 136, 185-186.	1.7	1
27	Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. <i>Annals of Neurology</i> , 2015, 77, 784-803.	5.3	78
28	Coagulation factor XII protease domain crystal structure. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 580-591.	3.8	48
29	The hypercoagulable profile of patients with stent thrombosis. <i>Heart</i> , 2015, 101, 1126-1132.	2.9	18
30	The role of activated coagulation factor XII in overall clot stability and fibrinolysis. <i>Thrombosis Research</i> , 2015, 136, 474-480.	1.7	33
31	Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1031-1043.e6.	2.9	120
32	Update on the role of extracorporeal CO2 removal as an adjunct to mechanical ventilation in ARDS. <i>Critical Care</i> , 2015, 19, 117.	5.8	21
33	Venous thrombosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15006.	30.5	216
34	Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4068-4073.	7.1	87
35	Normal range and genetic analysis of coagulation factor XII in the general Chinese population. <i>Thrombosis Research</i> , 2015, 136, 440-444.	1.7	4
36	Antithrombotic therapy for ventricular assist devices in children: do we really know what to do?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S343-S350.	3.8	21

#	ARTICLE	IF	CITATIONS
37	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. <i>Journal of the American Heart Association</i> , 2015, 4, e002322.	3.7	78
38	Venovenous Extracorporeal Membrane Oxygenation in Intractable Pulmonary Insufficiency: Practical Issues and Future Directions. <i>BioMed Research International</i> , 2016, 2016, 1-13.	1.9	20
39	Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. <i>Thrombosis and Haemostasis</i> , 2016, 115, 89-98.	3.4	42
40	A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin-Angiotensin Systems. <i>Frontiers in Medicine</i> , 2016, 3, 61.	2.6	16
41	Anticoagulation Management and Monitoring during Pediatric Extracorporeal Life Support: A Review of Current Issues. <i>Frontiers in Pediatrics</i> , 2016, 4, 67.	1.9	27
42	RNA an initiator of blood coagulation and inflammation. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2016, 27, 301-307.	0.1	0
43	The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats. <i>PLoS ONE</i> , 2016, 11, e0146783.	2.5	32
44	Advances in neonatal cardiac surgery. <i>Current Opinion in Cardiology</i> , 2016, 31, 109-116.	1.8	8
45	Factor XII: form determines function. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1498-1506.	3.8	62
46	Ion-Exchange Resin Anticoagulation (I-ERA). <i>Shock</i> , 2016, 46, 304-311.	2.1	4
47	FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis. <i>British Journal of Haematology</i> , 2016, 173, 769-778.	2.5	36
48	The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. <i>Critical Care</i> , 2016, 20, 387.	5.8	452
49	The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies. <i>Thrombosis Research</i> , 2016, 141, S4-S7.	1.7	22
50	Factor XI and factor XII as targets for new anticoagulants. <i>Thrombosis Research</i> , 2016, 141, S40-S45.	1.7	60
51	The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1099-1114.	2.2	57
52	Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived <i>Momordica cochinchinensis</i> Trypsin Inhibitor-II (MCoTI-II) Scaffold. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7287-7292.	6.4	34
53	Upstream versus downstream thrombin inhibition. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1273-1282.	1.5	4
54	Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. <i>Nature Communications</i> , 2016, 7, 12616.	12.8	61

#	ARTICLE	IF	CITATIONS
55	Antithrombotic potential of the contact activation pathway. <i>Current Opinion in Hematology</i> , 2016, 23, 445-452.	2.5	19
56	Haemostasis monitored in stored red blood cells, plasma and platelet concentrates in the proportion of 4. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 334-339.	1.0	3
57	Evidence of contact activation in patients suffering from ST-elevation myocardial infarction. <i>Thrombosis Research</i> , 2016, 141, 158-162.	1.7	4
58	On Target. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	2
59	A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. <i>Thrombosis Research</i> , 2016, 140, 118-124.	1.7	57
60	The Story of Angioedema: from Quincke to Bradykinin. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 51, 121-139.	6.5	38
61	The Alzheimer's disease peptide $\beta$ -amyloid promotes thrombin generation through activation of coagulation factor XII. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 995-1007.	3.8	87
62	Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 110, 181-194.	5.5	41
63	The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 28-39.	3.8	298
64	Cardiovascular disease in haemodialysis: role of the intravascular innate immune system. <i>Nature Reviews Nephrology</i> , 2017, 13, 285-296.	9.6	75
65	Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation. <i>Blood</i> , 2017, 129, 1527-1537.	1.4	79
66	Factor XII as a Risk Marker for Hemorrhagic Stroke: A Prospective Cohort Study. <i>Cerebrovascular Diseases Extra</i> , 2017, 7, 84-94.	1.5	12
67	Single-chain factor XII: a new form of activated factor XII. <i>Current Opinion in Hematology</i> , 2017, 24, 411-418.	2.5	14
68	Platelets and Coagulation. , 2017, , 447-462.		4
69	Factor XII Contact Activation. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 814-826.	2.7	89
70	Laboratory and clinical predictors of 30-day survival for patients on Extracorporeal Membrane Oxygenation (ECMO): 8-Year experience at Albert Einstein College of Medicine, Montefiore Medical Center. <i>Journal of Critical Care</i> , 2017, 40, 136-144.	2.2	14
71	Factor XIIa as a Novel Target for Thrombosis: Target Engagement Requirement and Efficacy in a Rabbit Model of Microembolic Signals. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 466-475.	2.5	10
72	Peptide Macrocyclic Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1151-1158.	6.4	45

#	ARTICLE	IF	CITATIONS
73	Emerging anticoagulant strategies. <i>Blood</i> , 2017, 129, 147-154.	1.4	58
74	Novel Antithrombotic Drugs on the Horizon. <i>Circulation Research</i> , 2017, 121, 1133-1135.	4.5	36
75	Proteolytic steps within signaling cascades make these signaling pathways irreversible. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 2057-2058.	4.1	0
77	Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1818-1828.	3.8	11
78	Discovery and assessment of water soluble coumarins as inhibitors of the coagulation contact pathway. <i>Thrombosis Research</i> , 2017, 157, 126-133.	1.7	12
79	Novel targets for anticoagulants lacking bleeding risk. <i>Current Opinion in Hematology</i> , 2017, 24, 419-426.	2.5	17
80	Prothrombotic aspects of sickle cell disease. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1307-1316.	3.8	36
81	The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 2118-2127.	4.1	114
82	A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1807-1817.	3.8	18
83	Hereditary Angioedema with Normal C1 Inhibitor. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 571-584.	1.9	43
84	Extracorporeal membrane oxygenation improves coagulopathy in an experimental traumatic hemorrhagic model. <i>European Journal of Trauma and Emergency Surgery</i> , 2017, 43, 701-709.	1.7	14
85	Anti-thrombotic technologies for medical devices. <i>Advanced Drug Delivery Reviews</i> , 2017, 112, 2-11.	13.7	72
86	MicroRNA-210 Enhances Fibrous Cap Stability in Advanced Atherosclerotic Lesions. <i>Circulation Research</i> , 2017, 120, 633-644.	4.5	98
87	Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 13-20.	2.4	108
88	A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection. <i>Thrombosis and Haemostasis</i> , 2017, 117, 44-56.	3.4	9
89	New developments in anticoagulants: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1283-1288.	3.4	81
90	Increased Carotid Artery Lesion Inflammation Upon Treatment With the CD137 Agonistic Antibody 2A. <i>Circulation Journal</i> , 2017, 81, 1945-1952.	1.6	6
91	Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis. <i>Frontiers in Immunology</i> , 2017, 8, 1115.	4.8	40

#	ARTICLE	IF	CITATIONS
92	Factors XI and XII as Targets for New Anticoagulants. <i>Frontiers in Medicine</i> , 2017, 4, 19.	2.6	69
93	The Effects of the Contact Activation System on Hemorrhage. <i>Frontiers in Medicine</i> , 2017, 4, 121.	2.6	23
94	Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients. <i>Chonnam Medical Journal</i> , 2017, 53, 110.	0.9	36
95	Coagulation factor XII in thrombosis and inflammation. <i>Blood</i> , 2018, 131, 1903-1909.	1.4	170
96	Plasma contact factors as therapeutic targets. <i>Blood Reviews</i> , 2018, 32, 433-448.	5.7	50
97	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 251-265.	3.4	44
98	2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 304-310.	2.4	31
99	Anticoagulation in neonatal ECMO. <i>Seminars in Perinatology</i> , 2018, 42, 122-128.	2.5	21
100	Introducing the pro-coagulant contact system in the numerical assessment of device-related thrombosis. <i>Biomechanics and Modeling in Mechanobiology</i> , 2018, 17, 815-826.	2.8	24
101	Potential of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 593-602.	2.1	6
102	A Flow Cytometry-Based Assay for Procoagulant Platelet Polyphosphate. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 369-373.	1.5	14
103	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3799-3822.	6.4	22
104	Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 060-069.	2.7	50
105	New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 71-86.	4.1	8
106	Emerging applications of aptamers for anticoagulation and hemostasis. <i>Current Opinion in Hematology</i> , 2018, 25, 382-388.	2.5	34
107	Current Understanding of How Extracorporeal Membrane Oxygenators Activate Haemostasis and Other Blood Components. <i>Frontiers in Medicine</i> , 2018, 5, 352.	2.6	137
108	Subverting bradykinin-evoked inflammation by co-opting the contact system: lessons from survival strategies of <i>Trypanosoma cruzi</i> . <i>Current Opinion in Hematology</i> , 2018, 25, 347-357.	2.5	14
109	Factor XII in inflammation and wound healing. <i>Current Opinion in Hematology</i> , 2018, 25, 403-409.	2.5	9

#	ARTICLE	IF	CITATIONS
110	Neonatal ECMO. <i>Frontiers in Medicine</i> , 2018, 5, 289.	2.6	29
111	Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1999-2009.	1.8	2
112	Future Antithrombotic Therapies in Cardiology. <i>Hamostaseologie</i> , 2018, 38, 236-239.	1.9	1
113	Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1355-1358.	2.9	31
114	Blood-device interaction. , 2018, , 597-626.		11
115	Incidence, Outcome, and Predictors of Intracranial Hemorrhage in Adult Patients on Extracorporeal Membrane Oxygenation: A Systematic and Narrative Review. <i>Frontiers in Neurology</i> , 2018, 9, 548.	2.4	64
116	Cell Receptor and Cofactor Interactions of the Contact Activation System and Factor XI. <i>Frontiers in Medicine</i> , 2018, 5, 66.	2.6	11
117	Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Non-aortic Cardiac Device Therapy—Current Evidence and Practice. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1590-1605.	3.4	9
118	Extracorporeal life support and systemic inflammation. <i>Intensive Care Medicine Experimental</i> , 2019, 7, 46.	1.9	79
119	Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: Review of the literature and alternative anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1608-1622.	3.8	45
120	The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 502-508.	2.7	49
121	Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis. <i>Cells</i> , 2019, 8, 716.	4.1	39
122	Crystal structures of the recombinant $\hat{1}^2$ -factor XIIa protease with bound Thr-Arg and Pro-Arg substrate mimetics. <i>Acta Crystallographica Section D: Structural Biology</i> , 2019, 75, 578-591.	2.3	14
123	Are Ticks the Answer to Medical Device-Associated Clotting?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2190-2192.	2.8	3
124	Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2178-2189.	2.8	31
125	Pharmaceutical applications of cyclotides. <i>Drug Discovery Today</i> , 2019, 24, 2152-2161.	6.4	24
126	Roles of Factor XII in Innate Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 2011.	4.8	65
127	Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1366-1375.	2.8	22



#	ARTICLE	IF	CITATIONS
128	Anticoagulation in Neonatal ECMO: An Enigma Despite a Lot of Effort!. <i>Frontiers in Pediatrics</i> , 2019, 7, 366.	1.9	25
129	Intrinsic Pathway of Coagulation and Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 331-338.	2.4	135
130	Antithrombotic Agents. <i>Circulation Research</i> , 2019, 124, 426-436.	4.5	76
131	BloodSurf 2017: News from the blood-biomaterial frontier. <i>Acta Biomaterialia</i> , 2019, 87, 55-60.	8.3	21
132	Expression and purification of recombinant serine protease domain of human coagulation factor XII in <i>Pichia pastoris</i> . <i>Bioscience, Biotechnology and Biochemistry</i> , 2019, 83, 1815-1821.	1.3	6
133	The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. <i>Acta Biomaterialia</i> , 2019, 94, 2-10.	8.3	148
134	Factor XII – What's important but not commonly thought about. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 599-606.	2.3	28
135	Use of C9/11 Mismatch-Control siRNA Reveals Sequence-Related Off-Target Effect on Coagulation of an siRNA Targeting Mouse Coagulation Factor XII. <i>Nucleic Acid Therapeutics</i> , 2019, 29, 218-223.	3.6	2
136	Antithrombotic Effect of shRNA Target F12 Mediated by Adeno-Associated Virus. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 295-301.	5.1	1
137	Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils. <i>Blood</i> , 2019, 133, 2090-2099.	1.4	23
138	Advances in understanding the molecular mechanisms of venous thrombosis. <i>British Journal of Haematology</i> , 2019, 186, 13-23.	2.5	31
139	Thromboembolic and Bleeding Complications in Transcatheter Aortic Valve Implantation: Insights on Mechanisms, Prophylaxis and Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 280.	2.4	31
140	AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 533-535.	2.4	7
141	An anticoagulant peptide from <i>Porphyra yezoensis</i> inhibits the activity of factor XIIa: In vitro and in silico analysis. <i>Journal of Molecular Graphics and Modelling</i> , 2019, 89, 225-233.	2.4	9
143	Neutrophil $\alpha$ -defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability. <i>Blood</i> , 2019, 133, 481-493.	1.4	48
144	Coevolution of the coagulation and immune systems. <i>Inflammation Research</i> , 2019, 68, 117-123.	4.0	20
145	Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. <i>Blood</i> , 2019, 133, 906-918.	1.4	408
146	From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors. <i>Blood Reviews</i> , 2020, 39, 100615.	5.7	35

#	ARTICLE	IF	CITATIONS
147	Effect of blood flow on platelets, leukocytes, and extracellular vesicles in thrombosis of simulated neonatal extracorporeal circulation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 399-410.	3.8	38
148	Acylated 1 <i>H</i> -1,2,4-Triazol-5-amines Targeting Human Coagulation Factor Xlla and Thrombin: Conventional and Microscale Synthesis, Anticoagulant Properties, and Mechanism of Action. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13159-13186.	6.4	21
149	Factor XII/Xlla inhibitors: Their discovery, development, and potential indications. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112753.	5.5	34
150	Toward a Long-Term Artificial Lung. <i>ASAIO Journal</i> , 2020, 66, 847-854.	1.6	23
151	The rebirth of the contact pathway: a new therapeutic target. <i>Current Opinion in Hematology</i> , 2020, 27, 311-319.	2.5	31
152	Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs. <i>Nature Communications</i> , 2020, 11, 3890.	12.8	61
153	Phosphorylcholine- and cation-bearing copolymer coating with superior antibiofilm and antithrombotic properties for blood-contacting devices. <i>Journal of Materials Chemistry B</i> , 2020, 8, 8433-8443.	5.8	22
154	Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function. <i>Thrombosis Research</i> , 2020, 196, 200-205.	1.7	13
155	Role of Kv1.3 Channels in Platelet Functions and Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2360-2375.	2.4	8
156	Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1087-1110.	2.3	8
157	Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 280.	2.7	9
158	Extracorporeal Artificial Organs and Therapeutic Devices. , 2020, , 1051-1077.		2
159	Cationic zinc is required for factor XII recruitment and activation by stimulated platelets and for thrombus formation in vivo. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2318-2328.	3.8	12
160	High-Throughput Docking and Molecular Dynamics Simulations towards the Identification of Potential Inhibitors against Human Coagulation Factor Xlla. <i>Computational and Mathematical Methods in Medicine</i> , 2020, 2020, 1-13.	1.3	4
161	Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation. <i>Kidney International Reports</i> , 2020, 5, 831-838.	0.8	10
162	Therapeutic strategies for thrombosis: new targets and approaches. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 333-352.	46.4	188
163	The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962092909.	1.7	26
164	The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. <i>Circulation Research</i> , 2020, 127, 571-587.	4.5	462

#	ARTICLE	IF	CITATIONS
165	Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 205-216.	2.3	29
166	Interplay between platelets and coagulation. <i>Blood Reviews</i> , 2021, 46, 100733.	5.7	147
167	Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 161-175.	2.1	12
168	A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies. , 2021, 218, 107676.		9
169	Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review. <i>ASAIO Journal</i> , 2021, 67, 290-296.	1.6	115
170	Dual inhibition of factor XIIIa and factor XIa as a therapeutic approach for safe thromboprotection. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 323-329.	3.8	21
171	Proteolytic activity of contact factor zymogens. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 330-341.	3.8	21
172	Xenotropic and polytropic retrovirus receptor 1 regulates procoagulant platelet polyphosphate. <i>Blood</i> , 2021, 137, 1392-1405.	1.4	21
173	Sulfated poly-amido-saccharides (sulPASs) are anticoagulants <i>in vitro</i> and <i>in vivo</i> . <i>Chemical Science</i> , 2021, 12, 12719-12725.	7.4	7
174	Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 218-232.	2.1	1
175	Factor XII plays a pathogenic role in organ failure and death in baboons challenged with <i>Staphylococcus aureus</i> . <i>Blood</i> , 2021, 138, 178-189.	1.4	15
176	Factor XIII Activity Might Already Be Impaired before Veno-Venous ECMO in ARDS Patients: A Prospective, Observational Single-Center Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1203.	2.4	7
177	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 319-329.	22.7	594
178	Upper Extremity Deep Vein Thrombosis: Current Knowledge and Future Directions. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 677-691.	2.7	4
179	Weekend effect in extracorporeal membrane oxygenation therapy initiation: a nationwide cohort study in South Korea. <i>Annals of Translational Medicine</i> , 2021, 9, 742-742.	1.7	2
180	Combination of polycarboxybetaine coating and factor XII inhibitor reduces clot formation while preserving normal tissue coagulation during extracorporeal life support. <i>Biomaterials</i> , 2021, 272, 120778.	11.4	28
181	Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. <i>EBioMedicine</i> , 2021, 67, 103382.	6.1	61
182	Potent Cyclic Peptide Inhibitors of FXIIa Discovered by mRNA Display with Genetic Code Reprogramming. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7853-7876.	6.4	14

#	ARTICLE	IF	CITATIONS
183	Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2158.	2.4	8
184	Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. <i>Thrombosis and Haemostasis</i> , 2021, , .	3.4	7
185	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 724-734.	2.7	3
186	The contact activation inhibitor ABO23 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2173-2184.	1.4	56
187	The contact system in liver injury. <i>Seminars in Immunopathology</i> , 2021, 43, 507-517.	6.1	18
188	Factor XII(a) inhibitors: a review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 1155-1176.	5.0	20
189	Myeloperoxidase has no effect on the low procoagulant activity of silica-free DNA. <i>Thrombosis Research</i> , 2021, 203, 36-45.	1.7	4
190	Biomaterial Wettability Affects Fibrin Clot Structure and Fibrinolysis. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100988.	7.6	15
191	Generation of a humanized FXII knockâ€”in mouseâ€”A powerful model system to test novel antiâ€”thrombotic agents. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2835-2840.	3.8	1
192	Mechanism, Functions, and Diagnostic Relevance of FXII Activation by Foreign Surfaces. <i>Hamostaseologie</i> , 2021, 41, 489-501.	1.9	6
193	Identification of the factor XII contact activation site enables sensitive coagulation diagnostics. <i>Nature Communications</i> , 2021, 12, 5596.	12.8	23
194	Thromboembolic Prophylaxis in Traumatic Brain Injury. , 2021, , 229-235.		0
196	Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis. <i>JCI Insight</i> , 2018, 3, .	5.0	23
197	Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. <i>Journal of Clinical Investigation</i> , 2015, 125, 3132-3146.	8.2	138
198	The delicate balance between pro-(risk of thrombosis) and anti-(risk of bleeding) coagulation during extracorporeal membrane oxygenation. <i>Annals of Translational Medicine</i> , 2016, 4, 139-139.	1.7	11
199	Hemostatic changes during extracorporeal membrane oxygenation: a commentary. <i>Annals of Translational Medicine</i> , 2016, 4, 140-140.	1.7	3
200	VITPOR AI, A Coagulation Factor XIIIa Inhibitor from <i>Porphyra yezoensis</i> : In Vivo Mode of Action and Assessment of Platelet Function Analysis. <i>Protein and Peptide Letters</i> , 2020, 27, 243-250.	0.9	2
201	Blood coagulation in the 21st century: existing knowledge, current strategies for treatment and perspective. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2020, 19, 139-157.	0.3	9

#	ARTICLE	IF	CITATIONS
202	Inhibition of factor XIIa, a new approach in management of thrombosis. <i>Annals of Translational Medicine</i> , 2015, 3, S20.	1.7	1
203	The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities. <i>Annals of Translational Medicine</i> , 2015, 3, 247.	1.7	23
204	New agents for thromboprotection. <i>Hamostaseologie</i> , 2015, 35, 338-350.	1.9	10
205	Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. <i>Drugs in Context</i> , 2019, 8, 1-11.	2.2	20
206	An update on factor XII-driven vascular inflammation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119166.	4.1	18
207	Pharmacological Inhibition of Factor XIIa Attenuates Abdominal Aortic Aneurysm, Reduces Atherosclerosis, and Stabilizes Atherosclerotic Plaques. <i>Thrombosis and Haemostasis</i> , 2022, 122, 196-207.	3.4	7
208	Coagulation Factor XII – A Key Pro-Inflammatory and Pro-Coagulant Protein. , 2016, , .		0
209	Drug Discovery for Coronary Artery Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1177, 297-339.	1.6	6
210	Changes in Coagulation Parameters After Permanent Pacemaker Implantation. <i>Medical University</i> , 2020, 3, 86-90.	0.2	0
211	Gerinnungsmanagement unter ECLS. , 2020, , 31-43.		0
212	Flow-Based Coagulation and Fibrinolysis Assays. , 2021, , 745-762.		0
213	Safe anticoagulation when heart and lungs are "on vacation". <i>Annals of Translational Medicine</i> , 2015, 3, S11.	1.7	3
214	Coagulopathy Characterized by Rotational Thromboelastometry in a Porcine Pediatric ECMO Model. <i>Journal of Extra-Corporeal Technology</i> , 2020, 52, 203-211.	0.4	1
215	Hemocompatibility enhancement of polyethersulfone membranes: Strategies and challenges. , 2021, 1, 100013.		11
216	Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). <i>Clinical and Translational Science</i> , 2022, 15, 709-720.	3.1	7
217	Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. <i>Nature Reviews Immunology</i> , 2022, 22, 411-428.	22.7	61
218	A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab. <i>Clinical and Translational Science</i> , 2022, 15, 626-637.	3.1	13
219	Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 524-534.	5.1	5

#	ARTICLE	IF	CITATIONS
220	Identification of the histidine-rich glycoprotein domains responsible for contact pathway inhibition. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 821-832.	3.8	3
221	COVID-19 Induced Coagulopathy (CIC): Thrombotic Manifestations of Viral Infection. <i>TH Open</i> , 2022, 06, e70-e79.	1.4	4
222	An Update on Safe Anticoagulation. <i>Hamostaseologie</i> , 2022, 42, 065-072.	1.9	3
223	New Blood Coagulation Factor XIIa Inhibitors: Molecular Modeling, Synthesis, and Experimental Confirmation. <i>Molecules</i> , 2022, 27, 1234.	3.8	11
224	Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 864899.	2.4	1
225	Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 240.	5.4	9
226	Chapter 4. Biological Consequences of the Blood-Surface Interaction. <i>RSC Detection Science</i> , 0, , 136-183.	0.0	0
233	Coagulation factors XI and XII as possible targets for anticoagulant therapy. <i>Thrombosis Research</i> , 2022, 214, 53-62.	1.7	12
234	The Antithrombotic Effect of Recombinant Neorudin on Thrombi. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 1667-1678.	4.3	2
237	Interactive Hemocompatible Nanocoating to Prevent Surface-Induced Coagulation in Medical Devices. <i>Advanced Materials Interfaces</i> , 2022, 9, .	3.7	5
238	Supercomputer Search for the New Inhibitors of the Coagulation Factor XIIa. <i>Lobachevskii Journal of Mathematics</i> , 2022, 43, 895-903.	0.9	2
239	Veno-Arterial Extracorporeal Membrane Oxygenation (ECMO) Impairs Bradykinin-Induced Relaxation in Neonatal Porcine Coronary Arteries. <i>Biomedicines</i> , 2022, 10, 2083.	3.2	1
240	Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 4932.	2.4	14
241	The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2023, 60, 25-40.	6.1	4
242	Early predictors of oxygenator exchange during veno-venous extracorporeal membrane oxygenation: A retrospective analysis. <i>International Journal of Artificial Organs</i> , 2022, 45, 927-935.	1.4	2
243	Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 5147.	2.4	28
244	Factor XII explored with AlphaFold - opportunities for selective drug development.. <i>Thrombosis and Haemostasis</i> , 0, , .	3.4	1
245	Mechanisms for Reduced Fibrin Clot Formation on Liquid-Infused Surfaces. <i>Advanced Healthcare Materials</i> , 2022, 11, .	7.6	6

#	ARTICLE	IF	CITATIONS
246	A fibrin enhanced thrombosis model for medical devices operating at low shear regimes or large surface areas. <i>PLoS Computational Biology</i> , 2022, 18, e1010277.	3.2	7
247	Bifunctional fusion protein targeting both FXIIa and FXIa displays potent anticoagulation effects. <i>Life Sciences</i> , 2022, 309, 121021.	4.3	3
248	Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation. <i>Blood Advances</i> , 2023, 7, 1404-1417.	5.2	6
249	Triazol-1-yl Benzamides Promote Anticoagulant Activity via Inhibition of Factor XIIa. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2023, 21, 108-119.	1.0	1
250	Experimentally Validated Novel Factor XIIa Inhibitors Identified by Docking and Quantum Chemical Postâ€­processing. <i>Molecular Informatics</i> , 2023, 42, .	2.5	3
251	Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 15698-15709.	6.4	0
252	Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 397.	1.6	2
253	Fit-for-purpose validation of a drug-tolerant immunogenicity assay for a human mAb drug in animal safety studies. <i>Journal of Immunological Methods</i> , 2023, 512, 113406.	1.4	1
254	Intrinsic coagulation pathway-mediated thrombin generation in mouse whole blood. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	5
255	Amide-functionalized 1,2,4-Triazol-5-amines as Covalent Inhibitors of Blood Coagulation Factor XIIa and Thrombin. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 1318-1347.	4.9	5
256	The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 744-755.	2.7	4
257	Outcomes of heparinized adult veno-arterial extracorporeal membrane oxygenation patients managed with low and high activated partial thromboplastin time targets: A systematic review and meta-analysis. <i>Perfusion (United Kingdom)</i> , 0, , 026765912211508.	1.0	0
258	HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure. <i>MAbs</i> , 2023, 15, .	5.2	0
259	Glycated albumin modulates the contact system with implications for the kallikrein-kinin and intrinsic coagulation systems. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 814-827.	3.8	1
260	Titanium is a potent inducer of contact activation: implications for intravascular devices. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 1200-1213.	3.8	7
261	Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease. <i>Blood</i> , 2023, 141, 1871-1883.	1.4	5
262	Inflammatory protection and management during extracorporeal membrane oxygenation. , 2023, , 1003-1020.		0
263	Current and future strategies to monitor and manage coagulation in ECMO patients. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	9

#	ARTICLE	IF	CITATIONS
264	Factor XII Silencing Using siRNA Prevents Thrombus Formation in a Rat Model of Extracorporeal Life Support. <i>ASAIO Journal</i> , 0, Publish Ahead of Print, .	1.6	0
265	The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 081-090.	2.7	6
266	Extracorporeal Circulation-Related Immune Response. <i>Lessons From the ICU</i> , 2023, , 85-112.	0.1	0
267	MarioHeart: Novel In-Vitro Flow Model for Testing Heart Valve Prostheses and Anticoagulant Therapies. <i>ASAIO Journal</i> , 0, Publish Ahead of Print, .	1.6	0
268	Advances in Enhancing Hemocompatibility of Hemodialysis Hollow-Fiber Membranes. <i>Advanced Fiber Materials</i> , 2023, 5, 1198-1240.	16.1	7
269	Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	2.7	1
270	NETs-Induced Thrombosis Impacts on Cardiovascular and Chronic Kidney Disease. <i>Circulation Research</i> , 2023, 132, 933-949.	4.5	8
271	Activated Coagulation FXII (Factor XII): A Unique Target for In Vivo Molecular Imaging. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 0, , .	2.4	0
272	Shear-Responsive Drug Delivery Systems in Medical Devices: Focus on Thrombosis and Bleeding. <i>Advanced Functional Materials</i> , 0, , .	14.9	2
273	Insights in the Prothrombotic Changes After Implantation of a Left Ventricular Assist Device in Patients With End-Stage Heart Failure: A Longitudinal Observational Study. <i>ASAIO Journal</i> , 2023, 69, 438-444.	1.6	0
274	Incidence of factor XII deficiency in critically ill patients with a prolonged activated partial thromboplastin time: a prospective observational study. <i>Blood Coagulation and Fibrinolysis</i> , 0, , .	1.0	0
275	Coagulopathy Characterized by Rotational Thromboelastometry in a Porcine Pediatric ECMO Model. <i>Journal of Extra-Corporeal Technology</i> , 2020, 52, 203-211.	0.4	1
276	DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2023, 12, 4984.	2.4	4
277	Anticoagulation in the ICU: a future for contact pathway inhibition?. <i>Intensive Care Medicine</i> , 0, , .	8.2	0
278	Anticoagulants in adult extracorporeal membrane oxygenation: alternatives to standardized anticoagulation with unfractionated heparin. <i>European Journal of Clinical Pharmacology</i> , 0, , .	1.9	0
279	An evolutionary history of <i>F12</i> gene: Emergence, loss, and vulnerability with the environment as a driver. <i>BioEssays</i> , 2023, 45, .	2.5	0
280	Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI. <i>Expert Review of Hematology</i> , 2023, 16, 711-714.	2.2	0
281	Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, , .	0.8	0



#	ARTICLE	IF	CITATIONS
282	Prevalence of FXII-Deficiency and Its Relevance to Monitoring Anticoagulation in Adults Receiving Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2024, 70, 217-223.	1.6	0
283	Factors XI and XII in extracorporeal membrane oxygenation: longitudinal profile in children. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102252.	2.3	0
285	Tissue Injury Protection: The Other Face of Anticoagulant Treatments in the Context of Ischemia and Reperfusion Injury with a Focus on Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17491.	4.1	0
286	Supercomputer Search for Coagulation Factor XIa Inhibitors in the Chinese National Compound Library. <i>Lecture Notes in Computer Science</i> , 2023, , 245-258.	1.3	0
287	Clotting of the Extracorporeal Circuit in Hemodialysis: Beyond Contact-Activated Coagulation. <i>Seminars in Nephrology</i> , 2024, , 151473.	1.6	1
288	Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease. <i>Seminars in Nephrology</i> , 2024, , 151484.	1.6	1
289	New Triazole-Based Potent Inhibitors of Human Factor XIa as Anticoagulants. <i>ACS Omega</i> , 2024, 9, 10694-10708.	3.5	0
290	Biomimetic Anticoagulated Porous Particles with Self-Reporting Structural Colors. <i>Advanced Science</i> , 0, , .	11.2	0